文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.

作者信息

Chen Lin, Tao Xuemei, Zeng Minghui, Mi Yuqiang, Xu Liang

机构信息

Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China; Department of Pathology and Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.

Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin, China; Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.

出版信息

J Hepatol. 2024 Feb;80(2):e64-e66. doi: 10.1016/j.jhep.2023.08.021. Epub 2023 Sep 14.

DOI:10.1016/j.jhep.2023.08.021
PMID:37714381
Abstract
摘要

相似文献

[1]
Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.

J Hepatol. 2024-2

[2]
Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.

Abdom Radiol (NY). 2024-9

[3]
Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.

J Gastroenterol Hepatol. 2024-7

[4]
Noninvasive tests maintain high accuracy for advanced fibrosis in chronic hepatitis B patients with different nomenclatures of steatotic liver disease.

J Med Virol. 2024-4

[5]
[Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].

Zhonghua Gan Zang Bing Za Zhi. 2024-4-20

[6]
Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.

Aliment Pharmacol Ther. 2024-7

[7]
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.

Aliment Pharmacol Ther. 2024-3

[8]
[NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].

Zhonghua Gan Zang Bing Za Zhi. 2023-8-20

[9]
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.

Front Nutr. 2024-7-8

[10]
Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?

Hepatol Int. 2024-2

引用本文的文献

[1]
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.

Front Med (Lausanne). 2025-8-14

[2]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[3]
Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population.

Gastroenterol Rep (Oxf). 2025-6-16

[4]
Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease.

Diagnostics (Basel). 2025-5-10

[5]
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches.

Biomolecules. 2025-5-5

[6]
Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders.

BMC Gastroenterol. 2025-5-14

[7]
A scientometric analysis and visualization of research on fatty liver diseases in Iran from 2003 to 2023.

J Diabetes Metab Disord. 2025-4-11

[8]
Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatment.

Ther Adv Endocrinol Metab. 2025-3-17

[9]
Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study.

Medicina (Kaunas). 2025-2-1

[10]
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Int J Mol Sci. 2025-2-13

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索